Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Nanjing Puenrui Biotechnology

Request full access

Oncology precision medicine R&D and CRO services

Nanjing City, ChinaFounded 2015

About Nanjing Puenrui Biotechnology

Nanjing Puenrui Biotechnology Co., Ltd. is a high-tech enterprise specializing in precision oncology diagnostics. Founded in 2015 by founder and chairman Zhu Yanping, the company is recognized as one of the first institutions in China to conduct in-vivo pharmacodynamic testing for individualized treatment. The firm serves over 100 domestic and international pharmaceutical companies with CRO services and provides individualized precision treatment services for cancer patients. Its business model centers on offering a one-stop service platform for tumor efficacy evaluation using its proprietary technologies and providing R&D for companion diagnostics.

Puenrui's core offering is its Patient-Derived Tumor Xenograft (PDTX) model platform, which includes patented technologies like FastPDTX® and HIS-PDTX (a dual-humanized model). These models simulate clinical trials in mice to assess the effectiveness of anti-tumor drugs, offering a faster and more precise method for drug sensitivity testing. The company has established a substantial biobank and database containing pharmacodynamic phenotype data, clinical phenotype information, and lifeomics data from living tumor tissues. This resource supports the development of companion diagnostic kits for anti-tumor drugs and new drug target discovery.

Financially, Puenrui has secured significant backing from various government and venture capital funds, including the National Science and Technology Achievement Transformation Guidance Fund. The company has completed multiple funding rounds, including a Series A in January 2019 and a Series B in December 2021 that raised over 200 million RMB. These funds are allocated to expanding the tumor biobank, enhancing CRO service capabilities, and accelerating the development and manufacturing of IVD test kits in its GMP-compliant facility. The company has received numerous accolades, including the title of "Nanjing Unicorn Cultivation Enterprise" in 2022.

Source: Dealroom company data

At a glance

Status
Operational
Employees
12
Open positions
2
Dealroom signal
17.3/100

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Jan 2022 $28M $110M Vision Plus Capital ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Nanjing Puenrui Biotechnology website traffic

Latest recorded traffic for Nanjing Puenrui Biotechnology is 120 monthly website visits. Nanjing Puenrui Biotechnology's team grew 0% over the past year.

Latest monthly visits120 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
2 distinct openings shownExplore hiring signals →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Nanjing Puenrui Biotechnology in the Nanjing City ecosystem

Live from Dealroom

The Nanjing Puenrui Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Vision Plus Capital
Employees 12 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Nanjing Puenrui Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nanjing Puenrui Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.